Transformed Probiotic Bacteria for Treatment of Chronic Diseases
用于治疗慢性疾病的转化益生菌
基本信息
- 批准号:7431222
- 负责人:
- 金额:$ 230.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-30 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-hydroxy-3-methylglutaryl-coenzyme AAcetatesActive SitesAcuteAcyl Carrier ProteinAcyltransferaseAdhesionsAdjuvantAdultAdverse effectsAffectAffinityAgeAldehydesAlkynesAmazeAmerican Type Culture CollectionAminesAmino Acid SequenceAmino AcidsAnabolismAnaerobic BacteriaAngiotensin IAngiotensin IIAngiotensin-Converting Enzyme InhibitorsAnimal ModelAnimalsAntibioticsAntibodiesAntigensAntioxidantsApolipoprotein A-IArachidonic AcidsArterial Fatty StreakAscorbic AcidAspergillusAtherosclerosisAttenuatedAutoantigensAutomobile DrivingAvidinAwardAzidesB-Cell ActivationB-LymphocytesBackBacteriaBacteriophagesBenignBifidobacteriumBindingBioavailableBiochemistryBiologicalBiological AssayBiological AvailabilityBiological ProcessBiologyBioreactorsBiotechnologyBiotinBiteBloodBlood CirculationBlood GlucoseBlood PressureBlood VesselsBolus InfusionCD4 Positive T LymphocytesCD80 AntigensCarbonCardiovascular DiseasesCaseinsCaspaseCause of DeathCell Adhesion MoleculesCell surfaceCellsCellular MembraneCellular biologyCessation of lifeCharacteristicsChemistryCholesterolChronicChronic DiseaseClinical TrialsCodeCodon NucleotidesCollaborationsComplementComplexConditionCoronary heart diseaseCosmidsCost SavingsCoupledCreativenessCuesCulture MediaCultured CellsDNADNA SequenceDailyDependenceDevelopmentDiabetes MellitusDietDigestionDiseaseDisease ProgressionDisease modelDoseDropsDrug CompoundingDrug Delivery SystemsDrug FormulationsDrug PrescriptionsDrug usageEatingEconomic BurdenEconomic InflationElderlyElementsEncapsulatedEndopeptidasesEnergy IntakeEngineeringEnsureEnterobacteriaceaeEnvironmentEnzyme GeneEnzyme InhibitionEnzymesEscherichia coliEssential GenesEventEvolutionExcretory functionF2-IsoprostanesFailureFamilyFatty AcidsFecesFeedbackFluorescenceFoodFood AdditivesFree RadicalsFunctional disorderFundingGastrointestinal tract structureGenerationsGenesGeneticGenomeGenomicsGlucoseGlycoproteinsGreen Fluorescent ProteinsGrowthHalf-LifeHealth BenefitHealthcare SystemsHearingHelper-Inducer T-LymphocyteHigh Density LipoproteinsHomeostasisHorizontal Gene TransferHormonesHourHumanHydro-LyasesHydrogen PeroxideHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl-CoA reductaseHypertensionHypoglycemiaHypotensionImageImmune responseImmunohistochemistryIn SituIn VitroIncubatedIndividualInflammationInflammatory ResponseInheritedInjection of therapeutic agentInjuryInstitutesInsulinInterventionIntestinesIntraperitoneal InjectionsInvadedIschemiaIschemic PreconditioningIsomerismJournalsKeto AcidsKetonesKineticsKnock-outKnowledgeLDL Cholesterol LipoproteinsLabelLactobacillusLactobacillus acidophilusLactobacillus caseiLeftLeptinLesionLibrariesLifeLightLinkLipid PeroxidationLipidsLiteratureLiverLocalizedLocationLongevityLongitudinal StudiesLovastatinLow Density Lipoprotein ReceptorLow-Density LipoproteinsLysineMass Spectrum AnalysisMeasuresMediatingMedicalMetabolicMethodsMethyltransferaseMicrobeMilkMindMinorMitomycinModelingModerate ExerciseModificationMoldsMolecular BiologyMolecular WeightMonitorMusMutationNADPH OxidaseNatureNeedlesNisinNumbersObese MiceObesityOncogenesOralOral AdministrationOxidative StressPathogenesisPathologyPathway interactionsPatientsPeptide HydrolasesPeptide Signal SequencesPeptidesPeptidyl-Dipeptidase APerformancePeroxidasePhage DisplayPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPhysical condensationPhysiologicalPhysiological ProcessesPhysiological reperfusionPilot ProjectsPlanet MarsPlasmaPlasmidsPolymerase Chain ReactionPopulationProbabilityProbioticsProceduresProcessProductionProductivityProlinePropertyProstaglandin ReceptorProstaglandin-Endoperoxide SynthaseProstaglandinsProtein BiosynthesisProtein OverexpressionProteinsProteolysisPurposePyridoxaminePyruvaldehydeQuality ControlRadioactivityRadiolabeledRangeRateRattusReactionReactive Oxygen SpeciesReagentRecombinantsRecruitment ActivityRegulationReperfusion InjuryReperfusion TherapyReportingResearch PersonnelResearch Project GrantsResistanceResourcesRestRiskRisk FactorsRoleRouteSafetyScheduleScienceScreening procedureSeriesSerumSerum AlbuminSideSignal TransductionSignaling MoleculeSiteSolutionsSolventsSorting - Cell MovementSourceSpecific qualifier valueSpecificitySpeedStandards of Weights and MeasuresSterilityStreamStretchingStructureSurfaceSystemT-LymphocyteTechniquesTechnologyTestingTherapeuticTherapeutic EffectTherapeutic UsesThinkingThymidineTimeTissuesToxic effectToxinTraining ProgramsTranslational ResearchTreatment CostTreatment EfficacyUnited StatesUniversitiesUnsaturated Fatty AcidsUpper armVariantVascular DiseasesWeekWhole OrganismWithdrawalWorkabsorptionabstractingadductanalogantigen antibody bindingantigen bindingbasecarbonyl compoundchemical synthesiscommensal microbescontrolled releasecostcycloadditioncyclooxygenase 1cyclooxygenase 2cytotoxicitydaydesigndesirediabeticdiariesdirect applicationdrug productiondrug synthesisenoyl reductaseepimerizationexperiencefallsfatty acid oxidationfield studygastrointestinalgene therapyhuman diseasehypercholesterolemiaimprovedin vivoinnovationinsightinsulin secretioninterestketoaldehydekillingslipophilicitymembermicrobialmimeticsmouse modelneutralizing antibodynovelnovel strategiesoxidationoxidized lipidoxidized low density lipoproteinpathogenic bacteriapeptide Lpeptide analogpeptide synthaseperoxidationphysical propertypillpolyketide synthasepressurepreventpromoterprotein aminoacid sequenceprotein crosslinkprotein degradationprotein expressionprotein functionradiotracerresearch studyresponseretireesizesmall moleculestoichiometrysynthetic enzymetetanus toxin fragment Ctherapeutic proteintherapeutic targettissue/cell culturetooltreatment durationtrendvectorvector vaccinewastingyoung adult
项目摘要
The continual increase in the number of patients suffering from chronic medical
conditions that require long term treatment with therapeutic drugs such as
hypercholesterolemia, hypertension, diabetes, and obesity has proven a tremendous
economic burden, both to individuals and to health care systems. The traditional
approach to drug production has been chemical synthesis of the needed compounds,
then purification, formulation, and distribution. We propose to investigate a novel
approach to long-term drug production and delivery: using probiotic intestinal bacteria
transformed to express the required drug and inoculated into a patient for chronic
colonization and therapeutic production. This approach essentially takes the notion of
gene therapy and rather than altering the genomic DNA of the patient, instead alters the
DNA of the patient's commensal bacteria, a far more tractable system. Probiotic
intestinal bacteria such as members of the Lactobacillus family are routinely added to
foods such as diary products, have essentially no pathology, and can be readily
transformed with exogenous DNA. Lactobacillus transformed with therapeutic proteins
and peptides or sets of enzymes to synthesize specific drugs may therefore represent a
versatile platform for sustainable therapy. We will determine the optimal strains of
Lactobacillus for expression in mice as a model organism and perform additional
engineering of the strain as necessary to ensure persistence in the intestinal tract and
regulated expression of peptide or proteins. We will also develop methods for rapidly
depleting the transformed bacteria without damaging other commensal bacteria, as a
safety precaution against the advent of any unexpected adverse responses during the
use of these therapeutically transformed bacteria. We will then examine the effect on
atherosclerosis-prone mice of expressing peptides with known therapeutic actions. Our
final aim will be to test the feasibility of producing small molecule drugs such as
lovastatin in vivo by transforming the bacteria with the required synthetic enzymes.
慢性病患者数量的持续增加
需要长期使用治疗性药物治疗的疾病,如
高胆固醇血症、高血压、糖尿病和肥胖已被证明是巨大的
对个人和卫生保健系统都造成经济负担。传统的
药物生产的方法是化学合成所需的化合物,
然后提纯、配制、分发。我们打算调查一部小说
长期药物生产和给药的途径:使用肠道益生菌
转化为表达所需药物并接种到患者体内进行慢性
殖民和治疗产品。这种方法本质上采用了
基因疗法不仅没有改变患者的基因组DNA,反而改变了
病人共生细菌的DNA,这是一个更容易处理的系统。益生菌
肠道细菌,如乳杆菌家族的成员,通常被添加到
食品,如乳制品,基本上没有病理,很容易
用外源DNA转化。治疗性蛋白转化乳杆菌的研究
因此,合成特定药物的多肽或酶组可能代表一种
可持续治疗的多功能平台。我们将确定最佳菌株
乳酸菌作为模式生物在小鼠中表达,并执行额外的
根据需要对菌株进行改造,以确保在肠道和
多肽或蛋白质的调节表达。我们还将开发快速的方法来
在不破坏其他共生细菌的情况下耗尽转化的细菌,作为
预防出现意外不良反应的安全预防措施
使用这些经过治疗转化的细菌。然后,我们将研究这一影响
易患动脉粥样硬化的小鼠表达具有已知治疗作用的多肽。我们的
最终目标将是测试生产小分子药物的可行性,如
洛伐他汀在体内通过用所需的合成酶转化细菌。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SEAN Stephen DAVIES其他文献
SEAN Stephen DAVIES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SEAN Stephen DAVIES', 18)}}的其他基金
Modification of HDL and Macrophage Function in Atherosclerosis
动脉粥样硬化中 HDL 和巨噬细胞功能的改变
- 批准号:
10544067 - 财政年份:2014
- 资助金额:
$ 230.25万 - 项目类别:
Modification of HDL and Macrophage Function in Atherosclerosis
动脉粥样硬化中 HDL 和巨噬细胞功能的改变
- 批准号:
10089343 - 财政年份:2014
- 资助金额:
$ 230.25万 - 项目类别:
Modification of HDL and Macrophage Function in Atherosclerosis
动脉粥样硬化中 HDL 和巨噬细胞功能的改变
- 批准号:
10327718 - 财政年份:2014
- 资助金额:
$ 230.25万 - 项目类别:
Therapeutically Modified Gut Bacteria for Treatment of Obesity
用于治疗肥胖症的治疗性修饰肠道细菌
- 批准号:
8843716 - 财政年份:2013
- 资助金额:
$ 230.25万 - 项目类别:
Therapeutically Modified Gut Bacteria for Treatment of Obesity
用于治疗肥胖症的治疗性修饰肠道细菌
- 批准号:
9042948 - 财政年份:2013
- 资助金额:
$ 230.25万 - 项目类别:
Therapeutically Modified Gut Bacteria for Treatment of Obesity
用于治疗肥胖症的治疗性修饰肠道细菌
- 批准号:
8481874 - 财政年份:2013
- 资助金额:
$ 230.25万 - 项目类别:
Therapeutically Modified Gut Bacteria for Treatment of Obesity
用于治疗肥胖症的治疗性修饰肠道细菌
- 批准号:
8656665 - 财政年份:2013
- 资助金额:
$ 230.25万 - 项目类别:
相似海外基金
Development of palladium-catalyzed novel organic transformations of silylated allyl acetates
钯催化的硅烷化乙酸烯丙酯新型有机转化的开发
- 批准号:
18K05101 - 财政年份:2018
- 资助金额:
$ 230.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Biosynthesis of Methylketones and 2-Alkany l Acetates
甲基酮和 2-烷酰基乙酸酯的生物合成
- 批准号:
9118188 - 财政年份:1992
- 资助金额:
$ 230.25万 - 项目类别:
Standard Grant














{{item.name}}会员




